➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Colorcon

Last Updated: July 16, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INLYTA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Inlyta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00700258 Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] Recruiting Pfizer N/A 2013-01-01 The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use
NCT01321437 Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Active, not recruiting Pfizer Phase 2 2011-12-01 The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
NCT01321437 Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Active, not recruiting University of California, Irvine Phase 2 2011-12-01 The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
NCT01529138 Study of Axitinib and Temsirolimus in Solid Tumors Completed Pfizer Phase 1 2011-10-01 This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.
NCT01529138 Study of Axitinib and Temsirolimus in Solid Tumors Completed Emory University Phase 1 2011-10-01 This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Inlyta

Condition Name

Condition Name for Inlyta
Intervention Trials
Clear Cell Renal Cell Carcinoma 5
Carcinoma, Renal Cell 3
Stage IIIB Melanoma 2
Metastatic Renal Cell Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Inlyta
Intervention Trials
Carcinoma, Renal Cell 16
Carcinoma 14
Melanoma 3
Carcinoma, Adenoid Cystic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Inlyta

Trials by Country

Trials by Country for Inlyta
Location Trials
United States 132
Japan 10
Russian Federation 6
Canada 5
Korea, Republic of 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Inlyta
Location Trials
California 9
Texas 7
Ohio 6
Florida 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Inlyta

Clinical Trial Phase

Clinical Trial Phase for Inlyta
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 21
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Inlyta
Clinical Trial Phase Trials
Recruiting 18
Not yet recruiting 12
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Inlyta

Sponsor Name

Sponsor Name for Inlyta
Sponsor Trials
Pfizer 12
National Cancer Institute (NCI) 4
Merck Sharp & Dohme Corp. 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Inlyta
Sponsor Trials
Industry 27
Other 26
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.